NCT00112918View on ClinicalTrials.gov

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

3,451

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2012

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL

Bevacizumab

Administered as an intravenous infusion over 30 - 90 minutes.

DRUG

Capecitabine

Film-coated tablets

DRUG

5-Fluorouracil (5-FU)

Administered as either a bolus injection or continuous intravenous infusion over 22 hours.

DRUG

Leucovorin calcium

Administered as a 200 mg/m\^2 infusion over 2 hours.

DRUG

Oxaliplatin

Administered as an intravenous infusion over 2 hours.

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Hoffmann-La Roche

INDUSTRY

NCT00112918 - Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | Biotech Hunter | Biotech Hunter